Search research articles
Contact Us
Filters
Showing results (31-40 of 50) with videos related to
Page
of 5
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 24, 2018
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
Jessica J Lin, Viola W Zhu, Adam J Schoenfeld, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis
Mark M Awad, Giulia C Leonardi, Sasha Kravets, et al.
JCO Precision Oncology
|
September 15, 2018
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an
Anna F Farago, Martin S Taylor, Robert C Doebele, et al.
Cancer Discovery
|
August 11, 2018
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 28, 2020
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
Kyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, et al.
Cancer Discovery
|
February 26, 2021
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial
Gregory J Riely, Joel W Neal, D Ross Camidge, et al.
Thyroid : Official Journal of the American Thyroid Association
|
November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
Vivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Cancer Discovery
|
April 11, 2022
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Mengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, et al.
The Lancet. Diabetes & Endocrinology
|
June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 50) with videos related to
Sort By:
Page
of 5
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 24, 2018
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
Jessica J Lin, Viola W Zhu, Adam J Schoenfeld, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis
Mark M Awad, Giulia C Leonardi, Sasha Kravets, et al.
JCO Precision Oncology
|
September 15, 2018
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an
Anna F Farago, Martin S Taylor, Robert C Doebele, et al.
Cancer Discovery
|
August 11, 2018
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 28, 2020
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
Kyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, et al.
Cancer Discovery
|
February 26, 2021
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations from a Phase I/II Trial
Gregory J Riely, Joel W Neal, D Ross Camidge, et al.
Thyroid : Official Journal of the American Thyroid Association
|
November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
Vivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Cancer Discovery
|
April 11, 2022
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Mengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, et al.
The Lancet. Diabetes & Endocrinology
|
June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
Page
of 5